O	0	10	Randomised
O	11	16	Phase
O	17	18	2
O	19	24	study
O	25	27	of
B-intervention	28	37	lapatinib
I-intervention	38	41	and
I-intervention	42	53	vinorelbine
O	54	56	vs
B-control	57	68	vinorelbine
O	69	71	in
B-eligibility	72	80	patients
I-eligibility	81	85	with
I-eligibility	86	90	HER2
I-eligibility	91	92	+
I-eligibility	93	103	metastatic
I-eligibility	104	110	breast
I-eligibility	111	117	cancer
I-eligibility	118	123	after
I-eligibility	124	133	lapatinib
I-eligibility	134	137	and
I-eligibility	138	149	trastuzumab
I-eligibility	150	159	treatment
O	160	161	(
O	161	165	KCSG
O	166	170	BR11
O	170	171	-
O	171	173	16
O	173	174	)
O	174	175	.

O	176	179	The
O	180	189	continuum
O	190	192	of
O	193	197	anti
O	197	198	-
O	198	202	HER2
O	203	209	agents
O	210	212	is
O	213	214	a
O	215	223	standard
O	224	233	treatment
O	234	236	of
O	237	241	HER2
O	242	243	+
O	244	254	metastatic
O	255	261	breast
O	262	268	cancer
O	269	270	(
O	270	273	MBC
O	273	274	)
O	274	275	.

O	276	280	This
O	281	286	study
O	287	296	evaluated
O	297	300	the
O	301	309	efficacy
O	310	312	of
O	313	322	lapatinib
O	323	327	plus
O	328	339	vinorelbine
O	340	342	in
O	343	351	patients
O	352	362	progressed
O	363	365	on
O	366	370	both
O	371	382	trastuzumab
O	383	386	and
O	387	396	lapatinib
O	397	407	treatments
O	407	408	.

O	409	410	A
O	411	416	total
O	417	419	of
B-total-participants	420	423	149
O	424	432	patients
O	433	437	were
O	438	446	randomly
O	447	455	assigned
O	456	458	to
O	459	468	lapatinib
O	469	473	with
O	474	485	vinorelbine
O	486	487	(
O	487	489	LV
O	489	490	)
O	491	492	(
O	492	493	n
O	494	495	=
O	496	498	75
O	498	499	;
O	500	509	lapatinib
O	509	510	,
O	511	515	1000
O	516	518	mg
O	519	524	daily
O	524	525	;
O	526	537	vinorelbine
O	538	540	20
O	541	543	mg
O	543	544	/
O	544	546	m2
O	547	549	D1
O	549	550	,
O	551	553	D8
O	554	557	q3w
O	557	558	)
O	559	561	or
O	562	573	vinorelbine
O	574	575	(
O	575	576	V
O	576	577	)
O	578	579	(
O	579	580	n
O	581	582	=
O	583	585	74
O	585	586	;
O	587	589	30
O	590	592	mg
O	592	593	/
O	593	595	m2
O	596	598	D1
O	598	599	,
O	600	602	D8
O	603	606	q3w
O	606	607	)
O	607	608	.

O	609	612	The
O	613	620	primary
O	621	629	endpoint
O	630	633	was
B-outcome-Measure	634	645	progression
I-outcome-Measure	645	646	-
I-outcome-Measure	646	650	free
I-outcome-Measure	651	659	survival
I-outcome-Measure	660	661	(
I-outcome-Measure	661	664	PFS
I-outcome-Measure	664	665	)
I-outcome-Measure	666	670	rate
I-outcome-Measure	671	673	at
I-outcome-Measure	674	676	18
I-outcome-Measure	677	682	weeks
O	682	683	.

O	684	687	The
O	688	694	median
O	695	701	number
O	702	704	of
O	705	713	previous
O	714	718	anti
O	718	719	-
O	719	723	HER2
O	724	733	therapies
O	734	737	was
O	738	739	2
O	740	741	(
O	741	746	range
O	747	748	2
O	748	749	-
O	749	750	5
O	750	751	)
O	751	752	.

O	753	758	There
O	759	762	was
O	763	765	no
O	766	777	significant
O	778	788	difference
O	789	791	in
B-outcome	792	795	PFS
I-outcome	796	800	rate
I-outcome	801	803	at
I-outcome	804	806	18
I-outcome	807	812	weeks
O	813	820	between
O	821	823	LV
O	824	827	and
O	828	829	V
O	830	834	arms
O	835	836	(
B-iv-bin-percent	836	838	45
I-iv-bin-percent	838	839	.
I-iv-bin-percent	839	840	9
I-iv-bin-percent	840	841	%
O	842	844	vs
B-cv-bin-percent	845	847	38
I-cv-bin-percent	847	848	.
I-cv-bin-percent	848	849	9
I-cv-bin-percent	849	850	%
O	850	851	,
O	852	853	p
O	854	855	=
O	856	857	0
O	857	858	.
O	858	860	40
O	860	861	)
O	861	862	.

B-outcome	863	866	ORR
O	867	870	was
B-iv-bin-percent	871	873	19
I-iv-bin-percent	873	874	.
I-iv-bin-percent	874	875	7
I-iv-bin-percent	875	876	%
O	877	879	in
O	880	882	LV
O	883	886	arm
O	886	887	,
O	888	891	and
B-cv-bin-percent	892	894	16
I-cv-bin-percent	894	895	.
I-cv-bin-percent	895	896	9
I-cv-bin-percent	896	897	%
O	898	900	in
O	901	902	V
O	903	906	arm
O	907	908	(
O	908	909	p
O	910	911	=
O	912	913	0
O	913	914	.
O	914	916	88
O	916	917	)
O	917	918	.

B-outcome	919	922	PFS
O	923	926	and
B-outcome	927	929	OS
O	930	933	did
O	934	937	not
O	938	944	differ
O	945	952	between
O	953	956	two
O	957	961	arms
O	962	963	(
O	963	965	LV
O	966	968	vs
O	969	970	V
O	970	971	;
B-outcome	972	978	median
I-outcome	979	982	PFS
O	982	983	,
B-iv-cont-median	984	986	16
O	987	989	vs
B-cv-cont-median	990	992	12
I-cv-cont-median	993	998	weeks
O	998	999	,
O	1000	1002	HR
O	1003	1004	=
O	1005	1006	0
O	1006	1007	.
O	1007	1009	86
O	1009	1010	,
O	1011	1013	95
O	1013	1014	%
O	1015	1017	CI
O	1018	1019	0
O	1019	1020	.
O	1020	1022	61
O	1022	1023	-
O	1023	1024	1
O	1024	1025	.
O	1025	1027	22
O	1027	1028	;
B-outcome	1029	1035	median
I-outcome	1036	1038	OS
O	1038	1039	,
B-iv-cont-median	1040	1042	15
I-iv-cont-median	1042	1043	.
I-iv-cont-median	1043	1044	0
O	1045	1047	vs
B-cv-cont-median	1048	1050	18
I-cv-cont-median	1050	1051	.
I-cv-cont-median	1051	1052	9
I-cv-cont-median	1053	1059	months
O	1059	1060	,
O	1061	1063	HR
O	1064	1065	=
O	1066	1067	1
O	1067	1068	.
O	1068	1070	07
O	1070	1071	,
O	1072	1074	95
O	1074	1075	%
O	1076	1078	CI
O	1079	1080	0
O	1080	1081	.
O	1081	1083	72
O	1083	1084	-
O	1084	1085	1
O	1085	1086	.
O	1086	1088	58
O	1088	1089	)
O	1089	1090	.

B-outcome	1091	1099	Toxicity
I-outcome	1100	1108	profiles
O	1109	1113	were
O	1114	1121	similar
O	1122	1124	in
O	1125	1129	both
O	1130	1134	arms
O	1135	1138	and
O	1139	1142	all
O	1143	1147	were
O	1148	1158	manageable
O	1158	1159	.

O	1160	1169	Lapatinib
O	1170	1174	plus
O	1175	1186	vinorelbine
O	1187	1196	treatment
O	1197	1200	was
O	1201	1210	tolerable
O	1210	1211	;
O	1212	1219	however
O	1219	1220	,
O	1221	1223	it
O	1224	1230	failed
O	1231	1233	to
O	1234	1245	demonstrate
O	1246	1249	the
O	1250	1258	clinical
O	1259	1267	benefits
O	1268	1272	over
O	1273	1284	vinorelbine
O	1285	1290	alone
O	1291	1293	in
O	1294	1302	patients
O	1303	1307	with
O	1308	1312	HER2
O	1313	1314	+
O	1315	1318	MBC
O	1319	1324	after
O	1325	1336	progression
O	1337	1339	on
O	1340	1344	both
O	1345	1356	trastuzumab
O	1357	1360	and
O	1361	1370	lapatinib
O	1370	1371	.

O	1372	1386	ClinicalTrials
O	1386	1387	.
O	1387	1390	gov
O	1391	1397	number
O	1398	1409	NCT01730677
O	1409	1410	.
